Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.
- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.
- “Geron’s tremendous science, expertise, clinical results and readiness to bring their first-in-class investigational telomerase inhibitor to the market have made this a very exciting time to join the Board,” said Dr. Aggarwal.
- Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.
- Dr. Aggarwal will serve as an independent Board member for Geron; his appointment to the Geron Board was not associated with an investment made either by him or by any investment firm.